Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

Literature DB >> 7818557

Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

B Kahaleh¹, M Matucci-Cerinic.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1995 PMID： 7818557 DOI： 10.1002/art.1780380102

Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591

Keyword Cloud
Cited

× No keyword cloud information.

24 in total

1. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

Authors: John Varga
Journal: Curr Rheumatol Rep Date: 2003-04 Impact factor: 4.592

2. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement.

Authors: R Livi; L Teghini; A Pignone; S Generini; M Matucci-Cerinic; M Cagnoni
Journal: Ann Rheum Dis Date: 2002-08 Impact factor: 19.103

3. Citalopram-induced Raynaud's phenomenon.

Authors: A M Peiró; C Margarit; M Torra
Journal: Rheumatol Int Date: 2006-11-14 Impact factor: 2.631

4. Raynaud's phenomenon and vitamin D.

Authors: Josiane Hélou; Roy Moutran; Ismael Maatouk; Fady Haddad
Journal: Rheumatol Int Date: 2012-05-12 Impact factor: 2.631

5. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

Authors: M Matucci-Cerinic; R Giacomelli; A Pignone; M L Cagnoni; S Generini; R Casale; P Cipriani; A Del Rosso; P Tirassa; Y T Konttinen; B M Kahaleh; P S Fan; M Paoletti; C Marchesi; M Cagnoni; L Aloe
Journal: Ann Rheum Dis Date: 2001-05 Impact factor: 19.103

6. Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.

Authors: Chieh-Yu Shen; Ko-Jen Li; Pei-Hsuan Lai; Chia-Li Yu; Song-Chou Hsieh
Journal: Clin Rheumatol Date: 2017-09-23 Impact factor: 2.980

Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone.

1. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.

2. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement.

3. Citalopram-induced Raynaud's phenomenon.

4. Raynaud's phenomenon and vitamin D.

5. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

6. Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.

7. Gastric dysmotility after liquid bolus ingestion in systemic sclerosis: an ultrasonographic study.

8. Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed by the COMPASS-31 Questionnaire.

Review 9. Recent achievements in the management of Raynaud's phenomenon.

10. Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis.